AI Insight
A research letter published in JAMA found that focal therapy remains rarely used for treating nonmetastatic prostate cancer patients across all risk categories. The study revealed that approximately 50% of patients who did receive focal therapy were classified as inappropriate candidates for this treatment approach, suggesting potential concerns about patient selection criteria.
Why it matters
This finding highlights a disconnect between the availability of focal therapy as a treatment option and its appropriate clinical application. The high rate of inappropriate use raises important questions about treatment guidelines, physician training, and patient selection protocols that could impact treatment outcomes and healthcare resource allocation for prostate cancer care.
Understand the Science
For patients with nonmetastatic prostate cancer, focal therapy use has remained uncommon across risk groups, and its use was defined as inappropriate in about half of recipients, according to a research letter published online Aug. 13 in the JAMA.
Source: Focal therapy use remains uncommon in nonmetastatic prostate cancer